Repligen Corporation to Present at William Blair 46th Annual Growth Stock Conference
Repligen (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, will participate in the William Blair 46th Annual Growth Stock Conference in Chicago.
Rhea-AI Summary
Repligen (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, will participate in the William Blair 46th Annual Growth Stock Conference in Chicago.
President and CEO Olivier Loeillot will present a company overview on June 3 at 10:40 a.m. CT, with a live and replay webcast via the Investor Relations website.
Positive
- None.
Negative
- None.
Details
News Market Reaction – RGEN
In the May 22 session, RGEN gained 1.49%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
- Conference edition
- 46th Annual
- William Blair Growth Stock Conference
- Presentation date
- June 3
- William Blair 46th Annual Growth Stock Conference
- Presentation time
- 10:40 a.m. CT
- Company overview session time
- Publication date
- May 22, 2026
- Press release announcement date
Historical Context
-
Release of 2025 Corporate Sustainability Report with multiple operational ESG milestones.
-
Announcement of participation in Bank of America 2026 Global Healthcare Conference.
-
Q1 2026 results with revenue growth and raised adjusted EPS guidance.
-
Scheduling announcement for first quarter 2026 earnings release and call.
-
Opening of European Training & Innovation Center in Breda, Netherlands.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
nasdaq financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
WALTHAM, Mass., May 22, 2026 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will participate in the William Blair 46th Annual Growth Stock Conference in Chicago, IL. Olivier Loeillot, President and Chief Executive Officer, will present a company overview on June 3rd at 10:40 a.m. CT.
A live webcast of the conference presentation will be accessible through Repligen’s Investor Relations website at www.repligen.com, and will be available for replay for a limited period of time following the event.
About Repligen Corporation
Repligen Corporation is a global life sciences company that develops and commercializes highly innovative bioprocessing technologies and systems that enable efficiencies in the process of manufacturing biological drugs. We are “inspiring advances in bioprocessing” for the customers we serve; primarily biopharmaceutical drug developers and contract development and manufacturing organizations (CDMOs) worldwide. Our focus areas are Filtration and Fluid Management, Chromatography, Process Analytics and Proteins. Our corporate headquarters are located in Waltham, Massachusetts, and the majority of our manufacturing sites are in the U.S., with additional key sites in Estonia, Germany, Ireland, the Netherlands and Sweden. For more information about the Company see our website at www.repligen.com, and follow us on LinkedIn.
Repligen Contact:
Jacob Johnson
VP, Investor Relations
781-419-0204
investors@repligen.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.